Opiant Pharmaceuticals (OPNT) – Press Releases
-
Deepwatch Names Mel Wesley as Chief Financial Officer
-
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
-
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
-
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
-
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
-
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
-
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
-
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
-
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
-
OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals
-
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
-
Indivior PLC to Acquire Opiant Pharmaceuticals
-
Indivior To Acquire Opiant Pharmaceuticals
-
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
-
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
-
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
-
MindMed Strengthens Board with Appointment of Two New Independent Directors
-
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
-
Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
-
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose
-
Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
-
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
-
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
-
Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
-
Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
-
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
-
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
-
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
-
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
-
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
-
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
-
Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release
-
Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone
-
Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone
-
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference
-
Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference
-
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
-
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
-
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
-
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
-
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
-
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
-
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
-
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
-
Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
-
Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
-
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Back to OPNT Stock Lookup
